ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EXOZ
ELUT (31) PTHS (20) INMB (30) CRBU (32) ⌘ Pro Terminal →

eXoZymes Inc. (EXOZ) — RQD Stock Rating Cockpit

$4.52 +9.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.59

eXoZymes Inc. (EXOZ) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $38.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EXOZ Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EXOZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, eXoZymes Inc. (NASDAQ: EXOZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.52 (+9.44% 1D, market cap $38.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EXOZ ranks #731 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EXOZ compare to ELUT and PTHS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EXOZ carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELUT (Elutia Inc. (Class A)) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.1M) and PTHS (Pelthos Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M). Among the 5-stock peer group, EXOZ leads on earnings multiple (N/A) while EXOZ leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EXOZ?
▼

Per EXOZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002010788), eXoZymes Inc. generated $27.2M in revenue (+63.8% YoY), -$9.2M in net income, and -$6.7M in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.59 (+1.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (9)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
$19 Bull$4 Base$3 Bear
📬 FREE EXOZ RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EXOZ)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY EXOZ SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$4.59-10.2% Next Q
Q2 (-2Q)
37
Grade E$4.12-7.8% Next Q
Q3 (-1Q)
35
Grade E$3.80+18.9% Next Q
Current
32
Grade E$4.52-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EXOZ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EXOZ currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.56) and Max Pain ($4.75) forces dealer call-delta covering toward $19.32.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EXOZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EXOZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
36.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE8% OF RANGE
L: $3$4.52H: $18
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on EXOZ

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-35.0% ROIC with 42.0% gross margin and -17.45% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

6/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like EXOZ
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EXOZ)

  • ✓Walkthrough of EXOZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EXOZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.44%▼ DESCENDING CHANNEL
2026-11-03O $4.11H $4.52L $4.11C $4.52VOL 6.1K
RES: $5.36SUP: $3.15SMA50: $5.56SMA200: $7.70
$11.86$9.53$7.19$4.85$2.51RES $5.36SUP $3.15$4.522026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EXOZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EXOZ Butterfly Map → + Track EXOZ →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +63.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EXOZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EXOZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EXOZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EXOZ)

Health Care Rank #731 of 1015 ⚔️ ELUT vs EXOZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EXOZ vs. ELUT, PTHS, INMB, CRBU)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, eXoZymes Inc. (EXOZ) ranks #731 by composite RQD confidence (32/100, grade E) and #772 by equity capitalization ($38.4M). Within this direct 5-issuer industry benchmark cohort, EXOZ leads on earnings valuation at N/A trailing P/E, while EXOZ leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. EXOZ currently leads its immediate peer cohort in composite quantitative strength at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EXOZ ACTIVE
eXoZymes Inc.
E 32/100 — — -35.0% +9.44% $38.4M Benchmark Subject
ELUT
Elutia Inc. (Class A)
E 31/100 — 53.7% -35.0% -1.92% $37.1M /elut-vs-exoz →
PTHS
Pelthos Therapeutics Inc.
E 20/100 — 76.3% -35.0% +22.55% $36.0M /pths-vs-exoz →
INMB
INmune Bio Inc.
E 30/100 — — -35.0% -4.83% $44.9M /inmb-vs-exoz →
CRBU
Caribou Biosciences Inc.
E 32/100 — — -35.0% +3.95% $45.4M /crbu-vs-exoz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002010788 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), eXoZymes Inc. (EXOZ) reported GAAP revenue of $27.2M (+63.8% vs. FY2024 revenue of $16.6M , and +38727.6% cumulative change since FY2023) , GAAP net income of -$9.2M, operating cash flow of -$6.5M, and free cash flow of -$6.7M (+25.1% YoY). On the balance sheet, EXOZ closed FY2025 with $6.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $27.2M -$9.2M -$6.5M -$6.7M $6.0M —
FY2024 (FY) 2024-12-31 $16.6M -$5.9M -$8.5M -$8.9M $13.0M —
FY2023 (FY) 2023-12-31 $70.1K -$2.0M -$1.2M -$1.2M — —

3. EXOZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EXOZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, eXoZymes Inc. (NASDAQ: EXOZ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.52 (+9.44% 1D, market cap $38.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EXOZ ranks #731 in composite RQD confidence.

How does EXOZ compare to ELUT and PTHS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EXOZ carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELUT (Elutia Inc. (Class A)) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.1M) and PTHS (Pelthos Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M). Among the 5-stock peer group, EXOZ leads on earnings multiple (N/A) while EXOZ leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EXOZ?

Per EXOZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002010788), eXoZymes Inc. generated $27.2M in revenue (+63.8% YoY), -$9.2M in net income, and -$6.7M in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EXOZ trading relative to its 50-day, 200-day, and 52-week technical levels?

EXOZ last traded at $4.52 (+9.44% on volume of 2,601 shares), positioning the stock -18.71% below its 50-day simple moving average ($5.56) and -41.30% below its 200-day simple moving average ($7.70). Across its 52-week range of $3.24 to $18.40, EXOZ sits at the 8.4% percentile with a 14-day RSI of 36.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.96 to $5.08).

Direct Sub-Reports: EXOZ RQD Cockpit EXOZ 12M Forecast EXOZ Earnings & Move EXOZ Dividends & DRIP EXOZ Insiders & 13F EXOZ Whale Options EXOZ Profit Sankey EXOZ News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

EXOZ — eXoZymes Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

eXoZymes Inc. (EXOZ) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.52 (+9.44% 1D, market capitalization $38.4M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -17.45%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

EXoZymes Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry (per the company profile). The profile reports a market capitalization of $0.0B, which conflicts with the $38.2M market capitalization in market data. The FY 2025 and FY 2024 filings report revenue of —, indicating no meaningful reported revenue in those periods ().

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), eXoZymes Inc. (EXOZ) reported $27.2M in annual revenue (up from $16.6M in FY2024, +63.8% YoY) and -$9.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($70.1K revenue, -$2.0M net income) through FY2025, EXOZ scaled operating cash flow to -$6.5M and free cash flow to -$6.7M, backed by $6.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.45% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.24 – $18.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Second-order bottlenecks cannot be identified from the provided sources. A prospective investor should note that the absence of mapped dependencies is itself a gap in the research, not evidence of independence.

  • Key Question #1: Can EXOZ sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $27.2M and free cash flow of -$6.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is EXOZ's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EXOZ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for eXoZymes Inc. (EXOZ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EXOZ Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EXOZ Bull vs. Bear Conversation Board — What's Your Call at $4.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EXOZ 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EXOZ:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $5.33 (+29.1%)
📌 Pinned Debate

The company holds $3.0M in reported cash and a 0.5 Debt/Equity ratio, and its Altman Z-Score of 2.5 sits in a range the rating cites as

The street is overcomplicating eXoZymes Inc. (EXOZ). The company holds $3.0M in reported cash and a 0.5 Debt/Equity ratio, and its Altman Z-Score of 2.5 sits in a range the rating cites as a moderate pillar score.. With an RQD score of 32/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $4.46.

RetailWhale_TX 🐂 BULL

Both sides have a point here — EXOZ's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $3.55 (-14.0%)
Spot @ $4.13

Negative ROIC of -35%, negative FCF yield of -17.45%, zero reported revenue, and a Piotroski F-Score of 2/9 point to continued cash bur

Negative ROIC of -35%, negative FCF yield of -17.45%, zero reported revenue, and a Piotroski F-Score of 2/9 point to continued cash burn and weak forensic health.. Look at the math on EXOZ: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $3.63 before getting long.

LIVE TAPE